PD-1 Blockade Shows Promise for mCRPC
For the first time, a study has provided evidence of meaningful clinical activity for programmed death 1 (PD-1) blockade in men with metastatic castration-resistant prostate cancer (mCRPC), according to a new report. In an ongoing phase II study, a team led by Julie N. Graff, MD, of the Oregon Health & Science University (OHSU) Knight…